Kasvu Therapeutics is a Helsinki-based biotech advancing a novel TrkB potentiator, KTX-0141, into clinical development for neuropsychiatric disorders including depression.
This profile is maintained by the Sesamers data desk. Claim it to edit details, post jobs and answer interviews.
-
Total raised
-
Valuation
-
Employees
-
Founded
Latest round
Series A - September 24, 2026
Series A - €30,000,000
September 24, 2026
Tesi, Innovestor Life Science Fund, Finnish Drug Discovery Center, Stephen Industries, Nordic Science Investments, Helsinki University Funds
✓ verified by our desk
Open roles
Kasvu Therapeutics is not hiring through Sesamers right now.
Work here? Claim the profile and post roles.
Claim your profile